See feature articles below:
About Broad Street Alerts:
Big opportunities in Small Cap’s
Broad Street Alerts recent profiles and track record, 217% in verifiable potential gains for our members on the last 4 small cap alerts alone!
February 10th, 2016- (NASDAQ: BONT) opened $1.65/share hit a high of $3.00/share within 30 days our member potential gains- 83%
March 7th, 2016-(NYSE-MKT: FSI) opened at .91/share and hit 1.10/share within 5 days for gains of 21% for our members.
March 24th, 2016- (NASDAQ: ICLD) opened at $.77/share it a high of $1.15/share within 2 days for gains of 49% for our members.
April 11th, 2016 – (NASDAQ: FNJN) called at $1.07/share hit $1.76/share in 3 days for 64% gains for our members.
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP SMS/text alert service for free, simply text the word “Alerts” to the phone number 25827 from your cell phone.
Report on:(Nasdaq: NEOT)
A number of investment brokers have recently updated their price targets on shares of Neothetics, Inc. (NEOT). According to the latest broker reports outstanding on Monday 25th of April, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.
Most recent broker ratings
12/15/2015 – Neothetics, Inc. was downgraded to “hold” by analysts at Needham & Company.
12/15/2015 – Neothetics, Inc. was downgraded to “neutral” by analysts at Piper Jaffray. They now have a USD 3 price target on the stock.
11/02/2015 – Neothetics, Inc. had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 16 price target on the stock.
The share price of Neothetics, Inc. (NEOT) was up +40.54% during the last day of trading, with a day high of 1.22. 4096632 shares were traded during the last session.
The stock’s 50 day moving average is 0.67 and its 200 day moving average is 3.67. The stock’s market capitalization is 14.28M. Neothetics, Inc. has a 52-week low of 0.53 and a 52-week high of 15.05.
Neothetics, Inc. is a clinical-stage specialty pharmaceutical company. The Company develops therapeutics for the aesthetic market. The Company’s initial focus is on localized fat reduction and body contouring. The Company’s lead product candidate LIPO-202 is an injectable treatment for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. The Company has completed Phase II development of LIPO-202. LIPO-202 is administered in a subcutaneous injection procedure that activates a natural metabolic process to shrink fat cells, without killing them, resulting in localized fat reduction, measurable results within four weeks and minimal risk with no downtime. The Company is also developing another product candidate LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate.
View other investors thoughts on Neothetics, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.
Source: Risers and Fallers
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
Broad Street Alerts was previously compensated eighteen thousand five hundred dollars by star media llc for the mention of FNJN however, that contract has expired.